Latest Proleukin Stories
Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/
Retrospective Analysis Demonstrates Survival Benefits for Patients with Stable and Progressive Disease after HD IL-2 in the Modern Era Suggesting Appropriate Drug Sequencing May Improve Outcomes
SAN DIEGO, March 1, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today highlighted its financial results and product development progress for the year ended December 31, 2010. "Prometheus had another record year in 2010, our 14th consecutive year of sales growth," said Joseph M.
SAN DIEGO, Oct. 11 /PRNewswire/ -- More than 120 cancer survivors and caregivers, cancer-treating physicians, and patient advocates gathered in San Diego to share their ProleukinÂ® (aldesleukin for injection) treatment experiences.
SAN DIEGO, June 2 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced that it will report new data on its proprietary oncology diagnostic platform, a novel technology that forms the basis of the Company's recently announced collaboration with Bayer Schering Pharma AG.
SAN DIEGO, Jan.
Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.
- totally perplexed and mixed up.